This page containing major gout news was last reviewed or updated on 19 August 2016.
On this page you can learn major news about gout, as selected by the editor, since the beginning of 2008.
We think significant news about gout is items such as when a new gout drug gains, or fails to gain, major medical authority approval; or there is a new genetic gout discovery; or there's a gout related controversy, or new major gout research.
And because so many gout-interested folk visit this site to learn about natural remedies for gout, we think natural gout remedy research (when it happens, unfortunately too rare) and real life events from diets or natural substances – that is major news about gout too.
The presentation order is latest gout news first.
August 2016 SEL212 (Pegsiticase) - money rasied for its develiopment. Selecta Biosciences, the company developing Pegsiticase has raised US$70 million to develop it via issuing shares. So it is now a public company quoted on the Nasdaq exchange with the stock code SELB, if you want to check its price. As I have said before I am enthusiastic about this drug turning out to be the best of all gout drugs
22 December 2015 We have a new gout drug. Lesinurad was approved by the US FDA just before Christmas 2015. Not long after, (January 2016), it was approved in EU nations. Plus Iceland, Norway and Liechtenstein, which are non EU. It can be prescribed as 200 mg tablets and must be used with a xanthine oxidase inhibitor drug – i.e. with allopurinol or febuxostat. It has been given the trade name, Zurampic. Our latest article about Lesinurad/Zurampic is here
10 June 2015 Selecta Biosciences announced the commencement of a Phase 1 trial of Pegsiticase/SEL-212. This marries a newtechnology to a gout biologic, and is probably the most interesting new gout drug under development. They aim for a non-immunogenic uricase, the best reducer of gout-causing uric acid. Read more here
13 August 2014 AstraZeneca PLC announced results for its three phase 3 trials of their new gout drug, Lesinurad. It was tested in combination with allopurinol and febuxostat. Results were good enough for the company to say that it will go ahead with applications for medical authority approval. Read more here.
April 2014 A proof-of-concept-programme (program) is underway for a new anti-inflammatory drug that may be applied in gout cases. It's called gevokizumab. Its previous name was Xoma-052.
13 December 2013 Pharma company AstraZenca PLC announced that in its phase three trial of the new gout drug Lesinurad (aka RDEA594) the target for the number of patrients who reduced their uric acid levels to below 6.0 mg/dL was met. But there were adverse events including serious ones. Lesinuard is currently in its last three phase 3 trials and their results are due to be announced by mid year 2014.
11 December 2013 Krystexxa has been acquired by Crealta Pharmaceuticals. Crealta's Chairman and CEO said this ensures Krystexxa's continued availability.
14 October 2013 The developers of the gout drug Krystexxa (pegloticase), Savient Pharmaceuticals, announced it had gone into Chapter 11 bankruptcy. But funds are available to keep Krystexxa supplied in the U.S.
10 January 2013 The gout drug Krysteexa (generic name: pegloticase) was approved by the European Medicines Agency for EU countries.
30 September 2012 Interesting news about cherries, one of the significant natural gout remedies. A report earlier this year from two professors of medicine, explained their three cherry trials and experiments. The results from all three trials showed that cherry juice concentrate often had a positive effect on gout's inflammation. In some cases (not all) gout attacks ceased and medications were discontinued. Read more here.
30 May 2012 A study, published online by the Annals of the Rheumatic Diseases Journal, has confirmed again that restricting your purine intake is important in treating gout. Analysis of 633 gout patients, and 1247 gout attacks over one year, by researchers at the Boston University School of Medicine found that those who consumed most purines had a nearly five times greater risk of a subsequent gout attack. Read the study’s abstract (main conclusions) here free courtesy of Annals of the Rheumatic Diseases at the British Medical Journal website (BMJ).
8 May 2012 An arthritis advisory committee (AAC) of the U.S. FDA voted 11 - 0 that it could not recommend Arcalyst's (rilonacept) approval. It is now highly unlikely the FDA will approve this potential new gout drug, but the developers may re-apply when they have studied it more. Read more about this here.
23 January 2012 Good news from a study. It's rare to read a natural remedy for gout study, but on this day a new one was published online about milk and gout. It found that gouty people who drank a glass of a milk product daily for 3 months lowered the frequency of their gout flares and gained other gout symptom benefits. Read more about this here.
21 June 2011 An Arthritis Advisory Committee of the U.S. FDA voted 11-1 against recommending Ilaris (canakinumab) to treat gout fares in patients who can't take NSAIDs or colchicine. It didn't think it is safe enough. Subsequently Ilaris was not approved by the FDA. Ilaris is also under approval consideration by E.U. countries, Switzerland and Canada.
4 May 2011 The developers of Krystexxa (pegloticase) applied for marketing approval in countries of the European Union. Expect a decision between July – December 2012.
21 January 2011 Japan approved Febuxostat, where its brand name will be Feburic.
5 November 2010 Krystexxa deliveries in the U.S. begin on 1 December 2010. Its full U.S. launch will be in February 2011. Read more about Krystexxa (Pegloticase) here.
And read this page which discusses its safety, patients' eligibility, side effects (of which there are many), and availability.
27 October 2010. Canada approves Febuxostat, where its brand name will be Uloric.
14 September 2010 The U.S. FDA has approved Krystexxa. (Pegloticase).
2 August 2009 The US FDA declined to approve Krystexxa (Pegloticase). But its reasons for doing so do not appear to be insurmountable. The drug's developers aim to reapply by early 2010.
29 July 2009 The U.S. FDA approves Colcrys, a Colchicine medication. Colchicine has been marketed in many countries in its modern form as a tablet since the 1930's, but in the U.S. it did not have FDA approval. It has now. And after a Colcrys study there's new knowledge about a safe Colchicine dose. Read about this here.
13 February 2009 The US FDA has approved febuxostat. Its brand name is Uloric in the U.S. Read more about this here, including prescribing information which can be downloaded.
December 2008 Britain's NICE (National Institute of Health and Clinical Excellence) approved febuxostat for certain categories of NHS gout patients. Read more about this here.
April 2008 Febuxostat was approved for use in member nations of the European Union (EU).
TESTIMONIALS ARE NEWS TOO
And don't forget the testimonials we receive. Gouty people talking about their real life experiences dealing with gout. It's news too, much of it about natural remedies for gout.
Our gout newsletter Don't expect more than three or four major gout news items a year, but if you want to regularly read less significant but still useful news about gout, subscribe to our free, gout newsletter, the Gout Dugout - use the link below to visit the sign up page.
We can't cover the world with this page. If you want secondary gout news from your country try a Search Engine search such as gout news (name of your country).